A RALGEF inhibitor suppresses lung cancer stem cell development and tumorigenesis
- 1Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky, USA
Abstract
Genetic studies have implicated RAL proteins as key components of RAS-mediated transformation and metastasis. They can modulate drug resistance, the cancer stem cell population and the exocyst transport system. RAL proteins are activated by RALGEFs (Guanine Nucleotide Exchange Factors). A conserved family of four RALGEFs serve as direct effectors of the RAS oncoprotein, connecting RAS to the regulation of RAL proteins. We have previously reported the development of a first-in-class small molecule inhibitor of RALGEFs that acts by binding to the RAS association domain of RALGEFs, blocking their interaction with RAS and suppressing the activation of RAL. Here we show the agent is active in KRAS-driven non-small cell lung cancer (NSCLC) models, both in vitro and in vivo using cell line and transgenic models of lung cancer. Moreover, we show that it acts to suppress the anti-porter activity of the RAL effector protein RALBP1, sensitises cells to standard-of-care treatment and suppresses the exocyst system. Finally, we show that it acts to suppress the cancer stem cell pool using biomarkers and tumor-forming unit assays. Thus, we identify a potential novel therapeutic approach to NSCLC.
Related
- SD-2102, a Novel PDK1 Inhibitor, Suppresses Lung Cancer Growth by Targeting PDK1/Akt Signaling Pathway
- E3 ubiquitin ligase MAGI3-mediated TAZ ubiquitination suppresses the non-small cell lung cancer occurrence and development by targeting the Wnt pathway
- Emerging roles and mechanistic insights of ASRGL1 in tumorigenesis and cancer progression
- Quorum sensing inhibitor-antibiotic conjugate suppresses virulence and eradicates intracellular Staphylococcus aureus.
- Podophyllotoxin suppresses growth of MFC gastric cancer cells by modulating DNA damage response-related gene expression
BibTeX
@article{jigo2026ralgef,
title = {{A RALGEF inhibitor suppresses lung cancer stem cell development and tumorigenesis}},
author = {Raphael Jigo and Geoffrey J. Clark},
journal = {The Journal of Biological Chemistry},
year = {2026},
month = sep,
doi = {10.1016/j.jbc.2026.113564},
url = {https://doi.org/10.1016/j.jbc.2026.113564},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A RALGEF inhibitor suppresses lung cancer stem cell development and tumorigenesis
AU - Raphael Jigo
AU - Geoffrey J. Clark
PY - 2026
DA - 2026/09/16
JO - The Journal of Biological Chemistry
DO - 10.1016/j.jbc.2026.113564
UR - https://doi.org/10.1016/j.jbc.2026.113564
AB - Genetic studies have implicated RAL proteins as key components of RAS-mediated transformation and metastasis. They can modulate drug resistance, the cancer stem cell population and the exocyst transport system. RAL proteins are activated by RALGEFs (Guanine Nucleotide Exchange Factors). A conserved family of four RALGEFs serve as direct effectors of the RAS oncoprotein, connecting RAS to the regulation of RAL proteins. We have previously reported the development of a first-in-class small molecule inhibitor of RALGEFs that acts by binding to the RAS association domain of RALGEFs, blocking their interaction with RAS and suppressing the activation of RAL. Here we show the agent is active in KRAS-driven non-small cell lung cancer (NSCLC) models, both in vitro and in vivo using cell line and transgenic models of lung cancer. Moreover, we show that it acts to suppress the anti-porter activity of the RAL effector protein RALBP1, sensitises cells to standard-of-care treatment and suppresses the exocyst system. Finally, we show that it acts to suppress the cancer stem cell pool using biomarkers and tumor-forming unit assays. Thus, we identify a potential novel therapeutic approach to NSCLC.
SN - 0021-9258
SN - 1083-351X
ER -